InvestorsHub Logo
Followers 130
Posts 13967
Boards Moderated 6
Alias Born 04/04/2008

Re: Mr_Lotto3000 post# 109

Friday, 01/08/2010 7:37:38 PM

Friday, January 08, 2010 7:37:38 PM

Post# of 320
Seems that this is a Subsidiary of APBI..

http://www.bizjournals.com/stlouis/stories/2010/01/04/daily64.html?ana=from_rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_stlouis+%28St.+Louis+Business+Journal%29

Notice this part..

In return, Accentia will give BioDelivery Sciences a warrant to purchase 2 million shares of Biovest, the SEC filing said.

And I am partial to this part:

Much of the focus is on BiovaxID, a personalized anti-lymphoma cancer vaccine that stimulates a patient’s own immune system to recognize and destroy cancerous cells. Early results from a Phase III clinical trial were promising, and additional data is expected to be filed in the next few months that could speed approval of the drug.

In anticipation of BiovaxID approvals, the company has started to expand a facility in Minneapolis where it will produce the vaccine.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.